Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants

详细信息    查看全文

• 作者：Milan J. Sonneveld^a ; ^{j.sonneveld@erasmusmc.nl} ; Vincent Rijckborst^a ; ^{v.rijckborst@erasmusmc.nl} ; Louwerens Zwang^b ; ^{l.zwang@erasmusmc.nl} ; Stefan Zeuzem^c ; ^{Zeuzem@em.uni-frankfurt.de} ; E. Jenny Heathcote^d ; ^{jenny.heathcote@utoronto.ca} ; Krzysztof Simon^e ; ^{krzysimon@gmail.com} ; Roeland Zoutendijk^a ; ^{r.zoutendijk@erasmusmc.nl} ; Ulus S. Akarca^f ; ^{ulusakarca@gmail.com} ; Suzan D. Pas^g ; ^{s.pas@erasmusmc.nl} ; Bettina E. Hansen^a ; ^h ; ^{b.hansen@erasmusmc.nl} ; Harry L.A. Janssen^a ; ^{h.janssen@erasmusmc.nl}
• 关键词：HBeAg ; Hepatitis B e Antigen ; CHB ; chronic hepatitis B ; HBV ; hepatitis B virus ; HBsAg ; hepatitis B surface antigen ; ALT ; alanine aminotransferase ; ULN ; upper limit of normal ; AUC ; area under the receiver-operating characteristic curve
• 刊名：Antiviral Research
• 出版年：2013
• 出版时间：March, 2013
• 年：2013
• 卷：97
• 期：3
• 页码：312-317
• 全文大小：553 K

文摘

Hepatitis B e antigen (HBeAg) levels may predict response to peginterferon (PEG-IFN) but are also influenced by presence of precore (PC) and core promoter (BCP) mutants.

HBeAg was measured in 214 patients treated with PEG-IFN ¡À lamivudine for 52 weeks. Patients were classified at baseline as wildtype (WT) or non-WT (detectable PC/BCP mutants). Combined response (HBeAg loss with HBV DNA < 2000 IU/mL), HBeAg response (HBeAg loss with HBV DNA > 2000 IU/mL) or non-response was assessed at week 78.

Mean baseline HBeAg levels were 2.65 logIU/mL in combined responders, 2.48 in non-responders and 2.24 in HBeAg responders (m>pm> = 0.034). Baseline HBeAg levels were not associated with combined response after stratification by WT/non-WT. Within the PEG-IFN monotherapy group (m>nm> = 104), patients with HBeAg < 1 logIU/mL at week 24 had a higher probability of combined response (29 % versus 12 % , m>pm> = 0.041). After stratification by WT/non-WT, WT patients with HBeAg < 1 logIU/mL at week 24 had a probability of combined response of 78 % (versus 19 % in patients with >1 logIU/mL, m>pm> < 0.001), whereas no difference in response rates was observed in non-WT patients (m>pm> = 0.848).

The relationship between HBeAg levels and response to PEG-IFN depends upon the presence of PC/BCP mutants. HBeAg levels should therefore not be routinely used to select patients for PEG-IFN, nor for monitoring of therapy.